Northwest Biotherapeutics Files Material Definitive Agreement

Ticker: NWBO · Form: 8-K · Filed: 2025-10-30T00:00:00.000Z

Sentiment: neutral

Topics: material-definitive-agreement

Related Tickers: NWBO

TL;DR

NWBO signed a big deal, details TBD.

AI Summary

Northwest Biotherapeutics, Inc. reported a material definitive agreement on October 24, 2025. The filing does not disclose specific details of the agreement, the other party involved, or any associated financial figures.

Why It Matters

This filing indicates a significant new agreement for Northwest Biotherapeutics, which could impact its business operations and future financial performance.

Risk Assessment

Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and implications of the material definitive agreement.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement?

The filing does not specify the nature of the material definitive agreement.

Who is the other party to this material definitive agreement?

The filing does not disclose the identity of the other party involved in the agreement.

What is the effective date of this agreement?

The earliest event reported is October 24, 2025, which is the date of the report and likely the effective date or date of entry into the agreement.

Are there any financial terms disclosed for this agreement?

No financial terms or dollar amounts related to the agreement are disclosed in this filing.

What is the purpose of this filing?

This Form 8-K is filed to report the entry into a Material Definitive Agreement by Northwest Biotherapeutics, Inc.

Filing Stats: 590 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2025-10-30 16:40:05

Key Financial Figures

Filing Documents

01

Item 1.01. Entry Into Material Definitive Agreement. Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, announced that its acquisition of Advent BioServices Ltd. ("Advent") has closed. As a result of this acquisition, Advent is now a wholly owned subsidiary of NWBio. As previously announced, through the acquisition of Advent, NWBio is receiving all of Advent's fixed assets, including extensive cryostorage and other equipment purchased by Advent over the last several years. Intellectual property and other intangibles that Advent had acquired are also included. The Company is not issuing any shares or other securities in connection with acquiring Advent. On the contrary, 19 million NWBio securities (13.5 million shares and 5.5 million options) that were previously issued to Advent as payment for contract services are reverting back to the Company along with the acquisition of the other Advent assets. The consideration for the acquisition will be paid in installments over two years, with potential acceleration after regulatory approval of the Company's DCVax -L product. The consideration consists of a payment of 1.4 million and payment of the net amount of accounts payable ("Net AP") already due from the Company to Advent for services under existing contracts. The acquisition agreement was updated to provide that the installment payments will not begin until 90 days after the October closing, rather than 90 days after the August agreement, and the Net AP is likewise being determined as of the closing date. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NORTHWEST BIOTHERAPEUTICS, INC. Date: October 30, 2025 By: /s/ Linda Powers Name: Linda Powers Title: Chief Executive Officer and Chairman

View on Read The Filing